{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T11:10:10Z","timestamp":1744542610862,"version":"3.40.4"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jdcr.2024.12.030","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:27:18Z","timestamp":1736987238000},"page":"118-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune checkpoint inhibitor-induced dyshidrotic eczema following tremelimumab therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-959X","authenticated-orcid":false,"given":"Raphaella","family":"Lambert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Stratman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-280X","authenticated-orcid":false,"given":"Grace","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-6159","authenticated-orcid":false,"given":"Jonas A.","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Niedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-0710","authenticated-orcid":false,"given":"Nicholas","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","key":"10.1016\/j.jdcr.2024.12.030_bib1"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.030_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.jdcr.2024.12.030_bib3","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous toxicities associated with immune checkpoint inhibitors: an observational, pharmacovigilance study","volume":"142","author":"Le","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2024.12.030_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40257-018-0376-3","article-title":"Retrospective chart review of cutaneous adverse events associated with tremelimumab in 17 patients","volume":"19","author":"Welborn","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.030_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/antib13030059","article-title":"Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database","volume":"13","author":"Frey","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"2","key":"10.1016\/j.jdcr.2024.12.030_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1016\/j.jdcr.2024.12.030_bib7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2024.12.030_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T10:55:23Z","timestamp":1744541723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":8,"alternative-id":["S2352512625000116"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.030","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-induced dyshidrotic eczema following tremelimumab therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}